Treatment of Acute Psoriasis Flare

Immediate Management Strategy

The American College of Dermatology recommends applying high-potency topical corticosteroid mixed 1:1 with calcipotriene twice daily for initial control during the acute flare 2
The European League Against Rheumatism suggests transitioning to weekend-only corticosteroid application with weekday calcipotriene to maintain remission while minimizing steroid exposure after 2 weeks of control 2
The maximum calcipotriol dose is 50 g/week to prevent hypercalcemia, as recommended by the National Psoriasis Foundation 2

The European League Against Rheumatism explicitly states that monotherapy with systemic corticosteroids is to be avoided in psoriasis because skin disease can flare during or after taper, with a strength of evidence level I 5
Systemic corticosteroids should be avoided in psoriasis due to the risk of severe rebound flares during or after tapering, with a high level of evidence 4, 1

The National Psoriasis Foundation recommends escalating beyond topical therapy if body surface area involvement is greater than 5%, with a moderate level of evidence 2
The American Academy of Dermatology suggests escalating therapy if there is an inadequate response to topical therapy after 4-8 weeks, with a high level of evidence 2
The European League Against Rheumatism recommends considering systemic therapy if there is significant impact on quality of life despite topical treatment, with a moderate level of evidence 2

The British Association of Dermatologists recommends phototherapy (UVB narrowband) as first-line systemic option, with a response time of 4 weeks and a high level of evidence 7
The American College of Rheumatology suggests methotrexate as a systemic treatment option, especially useful for acute generalized pustular psoriasis or erythrodermic psoriasis, with a moderate level of evidence 7, 3

The National Psoriasis Foundation recommends reassessing patients at 2-4 weeks to determine response to topical therapy, with a high level of evidence 2
The American Academy of Dermatology suggests monitoring for corticosteroid-induced complications, including skin atrophy, hypopigmentation, and HPA axis suppression with prolonged high-potency use, with a moderate level of evidence 2

The European League Against Rheumatism recommends considering methotrexate or TNF inhibitors early for patients with psoriatic arthritis, as they treat both skin and joint manifestations, with a high level of evidence 3